PLX

Over the past six months, Protalix BioTherapeutics experienced several stock-impacting events: a proxy statement filing on April 30, 2026; a $25.0 million milestone payment from Chiesi in May 2026 following European regulatory approval for Elfabrio's 2 mg/kg every-4-weeks dosing regimen; a U.S. patent term extension for Elfabrio until November 17, 2035, also in May; and Elfabrio's orphan drug marketing authorization in South Korea. On May 13, 2026, the company reported strong First Quarter 2026 financial results, including the milestone payment, leading to a net income of $18.2 million and a $51 million cash balance, reaffirming its 2026 revenue guidance. In July 2026, a new U.S. patent was issued for the PRX-115 uricase product candidate. On August 12, 2026, Protalix reported strong Second Quarter 2026 financial results, with revenues from selling goods increasing to $19.8 million, year-to-date total revenue reaching $53.6 million, and a net income of $3.8 million for Q2, with $40.7 million in cash and no outstanding debt. The company announced participation in prominent investor conferences in September 2026, and on October 5, 2026, Brazil's ANVISA approved Elfabrio for Fabry disease. The stock price has fluctuated between $1.60 and $3.19 over the past year, showing a 9.00% increase from October 7, 2025, to October 6, 2026.